These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6119205)

  • 1. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
    Sharp ME; Wallace SM; Hindmarsh KW; Brown MA
    Eur J Clin Pharmacol; 1981; 21(3):243-50. PubMed ID: 6119205
    [No Abstract]   [Full Text] [Related]  

  • 2. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.
    Goldstein PD; Alpers DH; Keating JP
    J Pediatr; 1979 Oct; 95(4):638-40. PubMed ID: 39125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].
    Eitner K; Reinicke C; Hippius M
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desensitization of patients with inflammatory bowel disease to sulfasalazine.
    Taffet SL; Das KM
    Am J Med; 1982 Oct; 73(4):520-4. PubMed ID: 6127032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance to therapy in patients on a maintenance dose of sulfasalazine.
    van Hees PA; van Tongeren JH
    J Clin Gastroenterol; 1982 Aug; 4(4):333-6. PubMed ID: 6126499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 11. [Appearance of sulfasalazine and sulfapyridine in breast milk and in the placental barrier as well as the effect of both substances on bilirubin binding to albumin].
    Järnerot G
    Z Gastroenterol Verh; 1981 Jun; 19():27-8. PubMed ID: 6168129
    [No Abstract]   [Full Text] [Related]  

  • 12. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.
    Das KM; Eastwood MA; McManus JP; Sircus W
    N Engl J Med; 1973 Sep; 289(10):491-5. PubMed ID: 4146729
    [No Abstract]   [Full Text] [Related]  

  • 14. Determination of sulfapyridine and its major metabolites in plasma by high pressure liquid chromatography.
    Fischer C; Klotz U
    J Chromatogr; 1978 Jul; 146(1):157-62. PubMed ID: 27529
    [No Abstract]   [Full Text] [Related]  

  • 15. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation.
    Esbjörner E; Järnerot G; Wranne L
    Acta Paediatr Scand; 1987 Jan; 76(1):137-42. PubMed ID: 2882643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
    Das KM
    Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man.
    Fischer C; Klotz U
    J Chromatogr; 1979 Feb; 162(2):237-43. PubMed ID: 33196
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of the colon in the metabolism of salicylazosulphapyridine.
    Das KM; Eastwood MA; McManus JP; Sircus W
    Scand J Gastroenterol; 1974; 9(2):137-41. PubMed ID: 4150441
    [No Abstract]   [Full Text] [Related]  

  • 19. Salazopyrin and its newer analogues in the treatment of inflammatory bowel disease.
    Banatwala N
    J Pak Med Assoc; 1985 Mar; 35(3):64-8. PubMed ID: 2860256
    [No Abstract]   [Full Text] [Related]  

  • 20. Sulphasalazine treatment during breast feeding.
    Järnerot G; Into-Malmberg MB
    Scand J Gastroenterol; 1979; 14(7):869-71. PubMed ID: 44005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.